Knowing that obesity is a significant CV risk factor, the scientific world is investigating incretin role in weight management, starting with glucagon-like peptide-1 receptor agonists (GLP-1 Ra) [14,15,16,17,18,19,20], to dual incretin tirzepatide in SURMOUNT program [21], to the GLP-1 and glucagon receptor agonist cotatutide [22], or even the triple incretin retatrutide [23], and the first results are promising in how clinicians could take action in the obesity pandemic. Here, GCG is linked to obesity disorder.